相似文献
1
Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1.
Am J Hum Genet. 1995 Mar;56(3):684-91.
2
Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the alpha 1, beta 1, and gamma subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect.
Hum Mol Genet. 1993 Jul;2(7):857-62. doi: 10.1093/hmg/2.7.857.
3
A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees.
Hum Mol Genet. 1997 Jun;6(6):953-61. doi: 10.1093/hmg/6.6.953.
4
A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
Hum Mol Genet. 2000 Jun 12;9(10):1515-24. doi: 10.1093/hmg/9.10.1515.
5
[What significance to genotype changes have in diagnosis of malignant hyperthermia?].
Anasthesiol Intensivmed Notfallmed Schmerzther. 1996 Aug;31(6):334-43. doi: 10.1055/s-2007-995932.
6
High-resolution physical mapping of four microsatellite repeat markers near the RYR1 locus on chromosome 19q13.1 and apparent exclusion of the MHS locus from this region in two malignant hyperthermia susceptible families.
Genomics. 1992 Nov;14(3):749-54. doi: 10.1016/s0888-7543(05)80179-x.
7
Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
Anesthesiology. 2001 Sep;95(3):716-25. doi: 10.1097/00000542-200109000-00026.
8
Genetic mapping of the beta 1- and gamma-subunits of the human skeletal muscle L-type voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility.
Hum Mol Genet. 1993 Jul;2(7):863-8. doi: 10.1093/hmg/2.7.863.
9
Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2.
Nature. 1990 Feb 8;343(6258):562-4. doi: 10.1038/343562a0.
10
Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families.
Hum Mol Genet. 1994 Jun;3(6):969-75. doi: 10.1093/hmg/3.6.969.
引用本文的文献
1
PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.
Pharmacogenet Genomics. 2015 Dec;25(12):622-30. doi: 10.1097/FPC.0000000000000170.
2
Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.
Anesthesiology. 2013 Nov;119(5):1054-65. doi: 10.1097/ALN.0b013e3182a8a998.
3
Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies.
Mol Genet Metab. 2011 Sep-Oct;104(1-2):167-73. doi: 10.1016/j.ymgme.2011.07.001. Epub 2011 Jul 12.
4
Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit.
Am J Physiol Cell Physiol. 2010 Dec;299(6):C1345-54. doi: 10.1152/ajpcell.00008.2010. Epub 2010 Sep 22.
5
Neurological channelopathies.
Postgrad Med J. 2005 Jan;81(951):20-32. doi: 10.1136/pgmj.2004.022012.
6
Screening for mutations in the RYR1 gene in families with malignant hyperthermia.
J Mol Neurosci. 2003;21(1):35-42. doi: 10.1385/JMN:21:1:35.
7
Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families.
J Med Genet. 1999 Feb;36(2):115-8.
8
Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families.
J Med Genet. 1998 Mar;35(3):196-201. doi: 10.1136/jmg.35.3.196.
9
Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors.
J Clin Invest. 1998 Mar 15;101(6):1233-42. doi: 10.1172/JCI993.
10
Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation.
Am J Hum Genet. 1998 Mar;62(3):599-609. doi: 10.1086/301748.
本文引用的文献
1
Genetic linkage analysis of chromosome 19 markers in malignant hyperthermia.
Br J Anaesth. 1993 Jan;70(1):70-5. doi: 10.1093/bja/70.1.70.
2
Genetic mapping of the beta 1- and gamma-subunits of the human skeletal muscle L-type voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility.
Hum Mol Genet. 1993 Jul;2(7):863-8. doi: 10.1093/hmg/2.7.863.
3
Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the alpha 1, beta 1, and gamma subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect.
Hum Mol Genet. 1993 Jul;2(7):857-62. doi: 10.1093/hmg/2.7.857.
4
Malignant hyperthermia hots up!
Hum Mol Genet. 1993 Jul;2(7):849. doi: 10.1093/hmg/2.7.849.
5
6
The genetics of malignant hyperthermia.
J Med Genet. 1993 Feb;30(2):89-93. doi: 10.1136/jmg.30.2.89.
7
Assignment of the human gene for the beta subunit of the voltage-dependent calcium channel (CACNLB1) to chromosome 17 using somatic cell hybrids and linkage mapping.
Genomics. 1993 Jan;15(1):185-7. doi: 10.1006/geno.1993.1029.
8
A novel SCN4A mutation causing myotonia aggravated by cold and potassium.
Hum Mol Genet. 1993 Sep;2(9):1349-53. doi: 10.1093/hmg/2.9.1349.
9
Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia.
Nat Genet. 1993 Sep;5(1):51-5. doi: 10.1038/ng0993-51.
10
A mutation in the human ryanodine receptor gene associated with central core disease.
Nat Genet. 1993 Sep;5(1):46-50. doi: 10.1038/ng0993-46.
Zotero 插件